Ind-Swift Laboratories Q2FY27 Results: Revenue Up 31.83% to ₹436.20 Cr, PAT Soars to ₹55.47 Cr
Ind-Swift Laboratories reported H1 FY27 revenue of ₹436.20 Cr (up 31.83%) and PAT of ₹55.47 Cr (up 3.3x). Q2 FY27 revenue was ₹242.49 Cr (up 25.18% QoQ). The company expects over 50% revenue growth in FY27 and a medium-term CAGR of 20-25%. It is net-debt-free with a ₹250 Cr capex program funded internally.
The substantial financial growth across key metrics, coupled with positive future guidance and a net-debt-free balance sheet, indicates a strong positive impact on the company's financial health and investor sentiment.
The company has reported significant year-on-year and quarter-on-quarter growth in revenue, operating EBITDA, and profit after tax. The management commentary also expresses strong confidence in future growth, with positive outlooks for revenue and EBITDA margins.
Ind-Swift Laboratories Limited has announced its un-audited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant increase in its financial performance, with total revenue for the half-year ended H1 FY27 reaching ₹436.20 crore, a substantial rise of 31.83% compared to ₹330.87 crore in H1 FY26.
Operating EBITDA for H1 FY27 grew substantially to ₹75.65 crore, with the operating EBITDA margin expanding to 17.97% from 5.47% in the previous year. Profit After Tax (PAT) for H1 FY27 surged to ₹55.47 crore, a significant increase from ₹16.88 crore in H1 FY26, with the PAT margin improving to 13.18% from 5.44%.
For the second quarter of FY27 (Q2 FY27), total revenue stood at ₹242.49 crore, marking a 25.18% increase quarter-on-quarter. Operating EBITDA for Q2 FY27 was ₹42.33 crore, with an operating EBITDA margin of 18.02%. PAT for the quarter was ₹31.03 crore, a 26.96% increase from the previous quarter, and the PAT margin stood at 13.21%.
The company's management commentary highlights a strong validation of strategic choices, with a transition from an API manufacturer to a focused FDF manufacturer. Operating income grew over 50% year-on-year, with operating EBITDA margin expanding to 18.02% and PAT margin to 13.21%. The company anticipates FY27 revenue growth of more than 50%, a medium-term revenue CAGR of 20-25%, and EBITDA margin expansion of 200-300 BPS. A ₹250 crore capex program is funded through internal accruals, and the company is net-debt-free.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.